The rapid release of new trial results for sodium-glucose cotransporter 2 inhibitor (SGLT2i) and emerging indications demonstrate an exciting new treatment for patients at high cardiovascular risk. Join this expert-led session to gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients.

	Webinar Join chair Alison Bailey, MD, FACC, and expert faculty Javed Butler, MBBS, FACC, Michelle Kittleson, MD, FACC, and Deepak L. Bhatt, MD, MPH, FACC for a virtual session to gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients. Meeting On Demand: Tracking the CV Impact of SGLT2i's: Practice Essentials
	Certified Patient Cases Apply your knowledge of SGLT2i’s and their role in CV risk reduction for high risk patients through these certified patient cases. Reducing Adverse Outcomes of Importance in HFrEF  Reducing MACE in a Patient With T2DM and ASCVD

Click here to see additional Spotlight Topics in the Clinical Spotlight Series